Brickell (NASDAQ: BBI) Is Only More Than Doubling Biotech Stock

Penny NASDAQ: BBI finally surpasses a $2 ceiling and heads to $3 after months of decline since mid-February. Brickell Biotech has been developing effective therapeutics for skin diseases for several years. Just hours ago, the company announced positive phase 3 pivotal study results Sofpironium Bromide. Thus, the stock jumped from $1.26 to $3.10 (in pre-market at 7:03 AM EDT).

Q1 2020 revenue is among the highest ever quarterly revenues that Brickell Biotech could achieve in recent years. Moreover, its Q1 2020 cost of revenue was cut by half to make the negative operating income closer to zero. Only huge revenue is needed to deliver significant earnings to dividend-focused stockholders.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life